IonQ and Kipu Quantum's 64-Qubit Protein-Folding Paper Took Third Place at IEEE Quantum Week 2026: Six Peptides, 46 to 61 Qubits, Four of Six Reference Energies Reached After Classical Post-Processing
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
A Kipu Quantum and IonQ paper on lattice protein folding took third place in the hybrid case-studies track at IEEE Quantum Week 2026 in Toronto, IonQ announced on 15 September 2026, and the release says the work "was used to improve computational speed and accuracy in drug discovery." The paper, on arXiv since 29 April 2026, reports something narrower: a hardware benchmark on six short peptides that reached the reference energy of a conventional solver in four cases, and only with the help of a classical consensus step.
The experiment ran six peptides of 14 to 16 residues through a 64-qubit trapped-ion processor, a barium development system IonQ describes as similar to its forthcoming Tempo line, folding each on a coarse lattice with no side chains using 46 to 61 qubits. The quantum circuits produced samples that mostly violated the backbone geometry, and it took a classical post-processing step, a consensus vote over the two thousand lowest-energy samples combined with a pool of feasible backbones, to reach the reference energy in four of the six cases; a random-start version of the same pipeline reached it in one. For a hospital buyer or a clinical pharmacologist that is the whole result: a hardware run on a benchmark, at a scale that a classical genetic algorithm solves to convergence, with the quantum contribution visible in the statistics of one part of the problem.
The IonQ release counts 857 submissions and 27 Best Paper honors at the conference, four of which went to papers with IonQ authors. Three of the four concern AI fine-tuning, distributed optimization with Oak Ridge National Laboratory and NVIDIA, and linear algebra with Synopsys. The fourth is the protein-folding paper with Kipu Quantum, which the release assigns to drug discovery. The conference's award list gives the paper third place in the Quantum End-to-End Hybrid Case Studies track, with the paper presented on Monday 14 September and the track's awards presented on Tuesday 15 September. Five of the fourteen authors are at Kipu Quantum in Berlin, one, Sebastián Romero, at ICMM-CSIC and the Autonomous University of Madrid, and eight at IonQ, among them Martin Roetteler, IonQ's vice president of quantum applications research, who is quoted in the release. The award recognizes a conference paper; it does not evaluate a drug, a target or a clinical claim, and the paper makes none.
QC Ware and IonQ Mapped Four Orbitals of a Cytochrome P450nor Active Site Onto Eight Qubits of IonQ Forte on 1 September 2026
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
How tightly a candidate binds its target is one important factor in whether a drug works, and metal centers are among the difficult cases to calculate: an iron atom sitting in the middle of an enzyme. On 1 September 2026 QC Ware and IonQ said they had measured a four-orbital slice of one such site on a quantum computer and landed close to the classical answer. QC Ware's Promethium platform did the classical preparation, IonQ's Forte trapped-ion processor took the quantum measurement through Amazon Braket, and the target was the heme active site of cytochrome P450nor. The workflow calculated an electrostatic interaction energy within 0.5 kcal/mol of classical benchmarks, roughly four percent, inside the one kcal/mol threshold conventionally called chemical accuracy.
The IonQ half of a workflow already run on IBM hardware
This is a follow-up. On 7 August 2026 this Monitor read the same QC Ware Promethium workflow running a nitric oxide reductase calculation on IBM's 156-qubit Heron processor. The platform, the enzyme family and the hybrid division of labor are unchanged; the processor underneath is what is new, which makes hardware portability the company's actual claim. Portability is not comparability: the August disclosure carried no numerical result that today's figure could be set against. Today's release adds four disclosures the August account did not carry: the 115-atom active-site model, its more than 1,000 molecular orbitals, the reduction to a four-orbital active space mapped onto eight qubits, and the 0.5 kcal/mol comparison itself.
What the quantum machine actually did
The quantum step ran on eight qubits of a 36-qubit machine, measuring a four-orbital slice carved out of a model containing more than a thousand molecular orbitals. Promethium built the model, identified the strongly correlated region, reduced it automatically to that active space, and computed the final interaction energies classically after Forte measured the qubits in a single basis. Everything before and after the quantum slice happened on classical hardware.
Which enzyme, and why the framing needs care
P450nor sits in the cytochrome P450 superfamily whose monooxygenase members carry out most human drug metabolism, and the release says exactly that. P450nor itself is something else: a fungal CYP55 nitric oxide reductase, characterized in Fusarium oxysporum among other fungi, reducing nitric oxide to nitrous oxide and taking its electrons straight from reduced nicotinamide adenine dinucleotide, NADH. The release names no organism and no accession. It is a well-characterized computational test case, which is a good reason to choose it for a hardware demonstration and a poor reason to describe the run as modeling human drug metabolism.
What the result can and cannot establish
The comparison target was a classical benchmark, so the classical answer existed first, and the companies report agreement for this known case. The announcement names no preprint, reports no shot count, gives no uncertainty on the 0.5 kcal/mol figure and does not identify which classical method produced the benchmark.
Tecnun's Synthetic Myelodysplastic-Syndrome Patients Were Seven-Bit Samples From IBM's ibm_basquecountry
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
The SintraREV trial randomized 61 patients. It ran from 15 February 2010 to 21 February 2018 across 22 university hospitals in Spain, France and Germany, and eight years of enrollment for 61 people is what a phase 3 study costs in a rare blood cancer. A preprint posted on 28 August 2026 takes the data from that trial and asks whether a quantum computer can generate synthetic patients good enough to stand alongside them.
Olatz Sanz Larrarte and nine co-authors published "A quantum generative model for in silico clinical trials using scarce training datasets" on arXiv on 28 August 2026, accepted for the proceedings of the CIBB 2026 conference. The author list crosses two worlds. Sanz Larrarte, Reza Dastbasteh, Pedro Crespo Bofill and Josu Etxezarreta Martinez work in the Department of Basic Sciences at Tecnun, the University of Navarra engineering school in San Sebastián. María Díez-Campelo of the hematology department at Hospital Universitario de Salamanca led SintraREV itself. Felipe Prosper and Ana Alfonso-Piérola practice at the Clínica Universidad de Navarra, Mikel Hernaez and Roberto Sanchez-Navarro sit at CIMA and DATAI in Pamplona, and Sara Capponi is at IBM Research in San Jose. The circuits ran on ibm_basquecountry, the 156-qubit Heron r2 processor in Donostia-San Sebastián.
Practical takeaway. The synthetic patients this pipeline produces are seven-bit strings. Sex, age, hemoglobin, platelets, neutrophils, treatment assignment and survival are each reduced to a single yes-or-no value, and the quantum processor samples from a distribution over those 128 possible patients. The fitting step that classical generative models spend hundreds of training epochs on happens on a classical computer before the quantum machine is touched.
Florida Atlantic's 90.26% Quantum Heart-Disease Result Came From a Simulator: the AI Paper of 21 May 2026 and the FAU Release of 27 August
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
Florida Atlantic University announced on 27 August 2026 that its engineers had built a quantum machine learning framework for heart disease prediction reaching more than 90 percent accuracy. The figure is precise and it is checkable. It is 90.26 percent, produced by a quantum support vector machine with angle encoding, averaged across five folds of a clinical file holding 918 patients.
The work behind that announcement appeared three months earlier. Muhammad Minoar Hossain, Md. Hasibul Hassan Himal and Arslan Munir published "A Comparative Study of Quantum Feature Maps and Quantum Classifiers for Heart Disease Prediction" in the MDPI journal AI on 21 May 2026, as article 180 of volume 7, under a Creative Commons license that lets anyone read the whole methods section. Section 2.6.2 of that paper states that every quantum experiment ran in a simulation-based environment rather than on a physical quantum processing unit. The university announcement does not carry that sentence, and neither does the coverage that followed it.
That difference decides what the study is evidence for. Simulated qubits establish whether an algorithm has promise in principle; a run on a physical processor establishes whether the machines that exist can deliver it, once noise, limited connectivity and readout error have had their say. Everything else in the paper holds up well under checking. Several of its numbers are more informative than the ones the announcement chose to lead with, and one of them disagrees with the paper's own abstract. The study is a careful piece of comparative work whose careful parts were the first thing lost in transmission.
A*STAR Put an 18-Variable Drug-Docking Problem on Six Qubits of IBM's ibm_kingston
Six qubits for an eighteen-variable docking problem
On August 20, 2026 six researchers at institutes of Singapore's Agency for Science, Technology and Research, the National University of Singapore and Nanyang Technological University posted a preprint describing a hybrid quantum-classical method for molecular docking, and executed its circuits on IBM's ibm_kingston processor. Molecular docking is the everyday question of early drug research: given a candidate molecule and a target protein, how does the molecule seat itself in the pocket, and how well. The team recast that question as a graph problem, where each plausible contact between ligand and protein is a weighted vertex and the winning binding pose is the heaviest set of contacts that can all coexist.
An encoding that carries three variables on one qubit
The contribution is an encoding the authors call full-basis encoding, which uses all three orthogonal directions of a qubit's Bloch sphere to carry information instead of one. That put an 18-variable problem on six qubits for the streptavidin-biotin complex 1STP, and a 14-variable problem on five qubits for trypsin with benzamidine, entry 9AW2. The paper also proves that a global minimizer of its objective can always be chosen to be a pure product state, so the optimum requires no entanglement between qubits and the circuits can stay shallow enough for current hardware. What changed for a reader tracking this field is the qubit cost of a docking problem, since the number of good qubits a problem consumes is the binding constraint on machines available today.
What the hardware runs did and did not settle
On both instances the runs on ibm_kingston recovered the same vertex selections as the classical simulation and matched the known clique structure under realistic gate noise and readout error. The authors state plainly that this is evidence of feasibility and that quantum advantage is not demonstrated, since both test problems were deliberately kept small enough for classical verification. Streptavidin with biotin and benzamidine in the trypsin pocket are textbook complexes, though their records differ in age: entry 1STP has been public since 1992, while entry 9AW2 is a 2025 redetermination of a complex first characterized in the mid-1970s. Either way the correct answer was known before the circuits ran, which is what made the check against ground truth possible and also what limits the claim. The open question the authors name themselves is whether the compression ratio survives realistic docking graphs with hundreds of vertices, alongside better ansatz design and hardware-aware circuit compilation.
Atrial Fibrillation Is Where Seoul Will Look for Quantum Advantage
A grant to find out whether quantum computing helps
On August 25, 2026 a Korean consortium was given two and a half years and 2.5 billion won to find out whether a quantum computer can compute cardiovascular blood flow on a schedule a clinic could live with. Seoul St. Mary's Hospital of the Catholic University of Korea, the University of Seoul and the medical software company Flownics were selected for a new 2026 challenge program run by Korea's Ministry of Science and ICT with the National Research Foundation. What the grant buys is a measurement rather than a product: the team has been funded to establish the conditions for quantum gain on one clinical calculation and to report those conditions as numbers, including how many circuits and how many measurements the answer cost.
What a hospital can already see, and what it cannot
A cardiologist reading a CT scan of a narrowed artery can measure the narrowing and cannot measure the flow. Velocity, pressure and wall shear stress are quantities that inform the risk of a clot forming or a muscle being starved, and none of them is in the picture. Computational fluid dynamics recovers them from the anatomy, and cardiology has begun buying it: pressure ratios computed from coronary CT are an established adjunct in stable chest pain assessment and have cleared a national payer's technology assessment in England. The trouble is what happens when a clinician asks for more. A finer mesh, honest nonlinear terms and patient-specific boundary conditions each multiply the arithmetic, and past a certain point the answer arrives too late to be part of a decision.
Atrial fibrillation first, adjudicated by imaging
The first target is atrial fibrillation, the most common sustained arrhythmia, present in roughly two to three percent of the population. In a fibrillating heart the left atrium stops emptying cleanly, blood stagnates in its appendage, and stagnation is where thrombus begins. Whatever the solver computes will be checked against real patients imaged with 4D Flow MRI, which records the speed and direction of the blood itself alongside the geometry of the vessels carrying it. The plan starts on classical hardware with a three-dimensional deep learning model that segments the heart, the left atrium and the aorta from CT, and a quantum hemodynamic model is built on top of that, stacking a variational algorithm, a Krylov subspace method, classical shadow measurement and non-Markovian error mitigation.
Ninety-five percent is a parity target
The headline figure deserves a careful reading. The stated aim is for quantum-based computational fluid dynamics to reach at least ninety-five percent of the precision of the classical method, which is a target to match the incumbent rather than to beat it. Any advantage the project finds will have to appear somewhere other than accuracy: in time to answer, in cost, or in problem sizes the classical solver cannot reach inside a clinical window. Stating it that way is unusually disciplined. The project fixes the accuracy at parity, names the baseline, names the disease, names the imaging modality that will adjudicate, and puts the burden of proof on resources. A hospital procurement officer has something to hold the team to in 2028, and a negative result in that year will be as informative as a positive one.
A Paid Quantum Drug Project Meets a Four-Stage Validation Ladder
The next calculation became funded work
China Securities Journal reported on August 14 that Shenzhen Jingtong Life Science tested Boson Quantum's approach on a drug-target structure problem in June and moved to a paid quantum drug-discovery engagement in July. The client named two difficult tasks: finding the precise binding conformation of a drug-target complex and calculating its energy after binding. It also reported an advantage in conformation search. The work now covers new molecules associated with healthy aging. The article says drug-related intellectual property would be jointly owned if the project succeeds, while software and algorithm rights would remain with Boson. The account is commercially meaningful because a buyer has funded a defined computational problem, yet the public article provides no molecule list, hardware configuration, classical baseline, runtime, success metric, or laboratory confirmation.
The same report sets a demanding standard
GuoDun Quantum executive Wang Zhehui supplied a four-stage validation ladder in the same article. It begins with benchmark advantage and initial industry validation on real quantum hardware. The decisive stages are superiority to classical algorithms under equal conditions and reproducible business outcomes. The engagement is commercially concrete, but the disclosed record cannot yet assign it a validation rung because real-hardware use and a controlled comparison remain undisclosed. Funded work may support learning, access, feasibility, or method development. It establishes customer demand without settling the scientific comparison.
The medical handoff remains ahead
Quantum computation would sit near the beginning of drug development. It may help decide which molecules deserve synthesis and testing, though it cannot establish safety, dosage, biological effect, or clinical benefit. Quentir reads the account as a useful commercial milestone with a built-in limit. The reported planned IP allocation recognizes a reusable computational method on one side and, if the project succeeds, a medicine that must survive laboratory, preclinical, and clinical work on the other. Paid work has started before a reproducible pharmaceutical result. The next public milestone that changes the judgment would connect an equal-condition computational comparison to a wet-lab result that another team can understand and repeat.
A Photosensitizer Has Two Jobs Before Quantum Computing Helps
Two molecular jobs define the target
A light-activated cancer drug must absorb light in a useful therapeutic window and turn that energy into chemistry that damages a tumor. Xanadu and the University of Alberta announced on August 13 that they will develop quantum algorithms for photosensitizer design. The research partnership follows a December 2025 preprint that specifies both desired outputs: cumulative absorption and intersystem crossing rates linked to reactive-oxygen production. The paper applies proposed fault-tolerant algorithms to BODIPY derivatives, including substitutions that are difficult for standard computational chemistry. This is a sharply defined pharmaceutical calculation, although the announcement reports no new molecular result, hardware run, candidate compound, or development timeline.
The resource estimate belongs to a future machine
The preprint studies active spaces of 11 to 45 spatial orbitals and estimates a need for roughly 180 to 350 logical qubits. Logical qubits are encoded across physical qubits and require error-correction overhead, so that estimate cannot be compared directly with headline physical-qubit counts. Xanadu therefore places the work in fault-tolerant quantum computing, while Professor Alex Brown contributes expertise in photodynamic therapy chemistry and the excited-state processes that classical methods struggle to capture. The partnership joins an algorithm team and a chemistry group around a named failure point in simulation. Its technology readiness remains early because no calculation has yet been reported on suitable hardware or checked against laboratory measurements.
Clinical usefulness still runs through the laboratory
Photodynamic therapy is an established local treatment for selected cancers and precancers, but better photosensitizer calculations must still survive pharmacology, toxicology, formulation, delivery, and trials. A future quantum result would need comparison with measured spectra, photochemical rates, and strong classical baselines. Quentir reads the partnership as a disciplined research bet: the biomedical quantities are prespecified, the molecular class is named, and the resource assumptions are public. Progress will become legible when the workflow reproduces a known molecule's behavior and then ranks unfamiliar candidates well enough to save synthesis cycles.
A Korean Pharma Webinar Names the Quantum Workload
The announcement names the computing path
KPBMA's first AI drug-discovery webinar, focused on quantum computing, is scheduled for August 13. Tech42 reports that SDT plans to present a hybrid quantum computing stack built around its QuREKA service. The announced environment links CPUs, GPUs, simulators, and quantum processors through a CUDA-Q development layer. Participants are also expected from QuantWare, Quantum Intelligence, and the Korea Research Institute of Bioscience and Biotechnology. The public account names molecular simulation, candidate search, and ADMET prediction as possible uses. Those are concrete pharmaceutical tasks, but the source remains an event preview. It provides no methods paper, dataset, benchmark table, candidate molecule, or measured advantage.
Portability can expose what the QPU contributes
The useful feature may be the ability to run one drug-discovery workload across different backends. A common development environment can keep the surrounding classical code visible while a team compares a simulator, GPU, and available QPU. That does not establish better performance. It can make the comparison easier to inspect. Runtime, accuracy, resource use, variance, and sensitivity to hardware noise all become part of the result. Pharmaceutical researchers can then ask whether the quantum step improves a defined endpoint or only changes the route used to compute it.
The pharmaceutical result is still open
ADMET covers how a drug is absorbed and distributed, how it is metabolized and excreted, and whether it is toxic. Each property depends on different data and validation methods. SDT's preview does not yet name an endpoint, baseline, or test set. Quentir therefore records two separate steps: SDT has described a multi-backend architecture, and KPBMA has created a pharmaceutical forum for it. Readiness for the announced applications remains unranked until a reported experiment shows what ran on the QPU, what stayed classical, and how the output compared with a strong existing method.
Madrid Is Buying a Quantum Computer for Hospitals to Share
Madrid has funded a shared quantum machine
The Comunidad de Madrid plans to buy a public quantum computer, install it at the Universidad Politécnica de Madrid, and make it available to universities, research centers, hospitals, companies, and technology startups. The regional government says the system will be delivered in 2029, with about EUR 2 million allocated through that year. Hospitals are explicitly inside the intended user community. The announcement is less specific about what they will do with the machine. It names no vendor, architecture, qubit count, medical project, clinical partner, performance result, or data pathway. Madrid has therefore made a concrete infrastructure commitment while leaving the medical program open.
Hospital access arrives before clinical utility
The phrase hospital access matters because it gives clinical and biomedical institutions a place in the future regional quantum community. Access does not establish a hospital deployment or a validated healthcare use. Medical relevance could eventually emerge through molecular simulation, optimization, biomedical analysis, or another problem that researchers have not yet formulated. Any such project will also inherit healthcare's demands for sensitive-data control, reproducibility, clinical accountability, and continuity of support. A public machine may reduce one barrier to experimentation. It cannot supply the missing use case, classical comparator, or validation path.
The service around the machine will decide its value
Computerworld Spain places Madrid beside existing quantum infrastructure in Barcelona, the Basque Country, and Galicia. Madrid's distinctive claim is regional public ownership. That choice creates a scientific commons whose future rules will shape which projects receive time and support. The useful comparison is a shared imaging or genomics facility: the apparatus matters, while skilled intermediaries make it usable. By 2029, the machine's presence will be easy to verify. More informative outcomes will include whether hospital teams used it, whether projects had strong classical comparisons, whether negative results remained available, and whether public ownership widened participation. Madrid has bought time to build that institution. The first medical contribution may be a clearer map of where quantum computing helps, where it does not, and what a credible next experiment requires.
A Quantum Clinical-Data Claim Stops Before the Benchmark
The workflow has a recognizable architecture
NeuroThera Labs said on July 29 that it had internally validated a proprietary quantum sampling workflow for continuous clinical and biomedical data. The company describes a hybrid process: continuous distributions are converted into energy-landscape representations, quantum dynamics propose samples, and a classical acceptance step preserves the intended distribution. This resembles a published line of quantum-enhanced Markov chain Monte Carlo research. It is a meaningful architecture claim. The release does not disclose the hardware, number of qubits, dataset, clinical task, circuit depth, runtime, convergence diagnostics, or classical comparator.
Correctness and performance remain separate
An acceptance mechanism can protect the target distribution without showing that a sampler reaches useful regions quickly. The missing benchmark gap covers effective sample size, autocorrelation, mixing time, wall-clock cost, encoding overhead, calibration, and repeated-run stability. A 2023 Nature paper by David Layden and colleagues reported fewer iterations than common classical alternatives on tested Ising-model instances and treated larger-scale speedup as conditional. A 2024 analysis by Alev Orfi and Dries Sels found no speedup for a worst-case unstructured problem in the proposal class they studied. Neither result decides NeuroThera's undisclosed implementation. Together they show why problem structure and comparative testing matter.
The company's own release says the work is preliminary, internally validated, unreviewed, and not independently verified. It also says the platform is a research and analytics tool, not a medical device or diagnostic, and that no quantum advantage is assured. For clinical data, the comparison would also need to show that encoding preserves missingness, correlated variables, rare subgroups, and uncertainty. A faster chain through a distorted distribution would not support the intended analysis. The next useful disclosure would join the hardware run, statistical diagnostics, and preservation of clinically relevant data features in one reproducible comparison. Until then, the announcement is best read as an engineering checkpoint rather than a clinical performance result.